Parenteral Nutrition Market Size & Growth Forecast 2027–2036, By Segments (Stage Type, Sales Channel, Nutrient Type, Indication), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Parenteral Nutrition Market size was around USD 8.4 billion in 2026 and is slated to grow at a 5.61% CAGR from 2027 to 2036, crossing USD 14.5 billion by 2036. The industry revenue for 2027 is estimated at USD 8.8 billion.

• Base Year Value (2026): USD 8.4 billion
• CAGR (2027-2036): 5.61%
• Forecast Year Value (2036): USD 14.5 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Parenteral Nutrition Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America accounted for a 43.99% market share in 2026, supported by established hospital infrastructure, standardized clinical nutrition practices, and routine use across intensive and specialized care settings.
  • Asia Pacific is expected to expand at a 6.89% CAGR, driven by improving hospital capacity, wider access to critical care, and growing adoption of clinical nutrition therapies across larger patient populations.

• Segment Momentum:

  • Adults accounted for 82.75% of the market in 2026 due to widespread use of parenteral nutrition in hospital care for patients requiring nutritional support during major illness, surgery, or cancer treatment.
  • Online sales are growing fastest because digital procurement improves purchasing convenience, repeat ordering, and product access, particularly as home-based care and outpatient nutrition management become more organized.

• Market Expansion Drivers:

  • Rising cancer prevalence and gastrointestinal disorders increasing demand for intravenous nutritional support.
  • Expanding home parenteral nutrition adoption and advanced multi-chamber formulations improving patient outcomes.
  • Increasing premature birth rates accelerating neonatal and pediatric parenteral nutrition utilization.

• Leading Market Participants:

  Prominent players in the parenteral nutrition market include Baxter International Inc. (United States), Fresenius Kabi AG (Germany), B. Braun SE (B. Braun Melsungen AG) (Germany), Otsuka Pharmaceutical Factory, Inc. (Japan), Grifols, S.A. (Spain), Pfizer Inc. (United States), ICU Medical, Inc. (United States), Sichuan Kelun Pharmaceutical Co., Ltd. (China), JW Pharmaceutical Corporation (South Korea), CSL Limited (Australia).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 8.4 billion
  • 2027 Estimated Market Size: USD 8.8 billion.
  • Projected Market Size: USD 14.5 billion by 2036
  • Growth Forecasts: 5.61% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Adult (Stage Type) | Institutional (Sales Channel) | Single Dose Amino Acid Solution (Nutrient Type) | Cancer (Indication)
  • Emerging Opportunity Segment: Pediatrics (Stage Type) | Online (Sales Channel) | Parenteral Lipid Emulsion (Nutrient Type) | Dysphagia (Indication)

Market Growth Drivers and Industry Trends

Rising cancer prevalence and gastrointestinal disorders increasing demand for intravenous nutritional support

The growing incidence of cancer and gastrointestinal disorders will drive the parenteral nutrition market as patients who cannot obtain adequate nutrition through normal gastrointestinal function require intravenous nutritional support. Cancer treatments, digestive disorders, surgical procedures, and severe intestinal complications can interfere with nutrient absorption or oral intake, creating a need for formulations that deliver essential nutrients directly into the bloodstream. Hospitals and specialized care facilities therefore rely on parenteral nutrition to support patients during periods of nutritional insufficiency, particularly when enteral feeding is not feasible or clinically appropriate.

Expanding home parenteral nutrition adoption and advanced multi-chamber formulations improving patient outcomes

Expansion of home-based nutritional care is supporting the parenteral nutrition market by allowing suitable patients to continue intravenous nutritional therapy outside traditional hospital environments. Home administration can reduce prolonged hospitalization requirements while supporting continuity of nutritional support for individuals with chronic intestinal or digestive conditions. At the same time, multi-chamber formulations simplify preparation and can improve handling of complex nutritional regimens by combining key nutrient components within convenient delivery systems, helping healthcare professionals manage nutritional requirements more consistently.

Increasing premature birth rates accelerating neonatal and pediatric parenteral nutrition utilization

Higher numbers of premature infants are contributing to the parenteral nutrition market because neonatal patients may have immature gastrointestinal systems and require specialized nutritional support during early development. Parenteral nutrition provides essential nutrients when premature infants are unable to tolerate sufficient enteral feeding, supporting growth and physiological development under intensive clinical supervision. Neonatal formulations can be tailored to the nutritional requirements of developing infants, with careful management of proteins, carbohydrates, lipids, electrolytes, vitamins, and minerals in specialized hospital settings.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising cancer prevalence and gastrointestinal disorders increasing demand for intravenous nutritional support	2.00%	High	North America, Europe	High	Near Term
Expanding home parenteral nutrition adoption and advanced multi-chamber formulations improving patient outcomes	1.70%	Moderate	North America, Asia Pacific	High	Mid Term
Increasing premature birth rates accelerating neonatal and pediatric parenteral nutrition utilization	1.50%	Moderate	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest share of the parenteral nutrition market at 43.99% in 2026, reflecting the region's advanced hospital infrastructure, high prevalence of complex medical conditions requiring nutritional support, and widespread availability of specialized clinical nutrition services. Strong capabilities in critical care, oncology, gastrointestinal care, and neonatal medicine sustain demand for parenteral nutrition when enteral feeding is unsuitable or insufficient. Established healthcare systems, trained clinical nutrition professionals, and greater adoption of technologically advanced nutritional formulations further reinforce the region's market position. Continued emphasis on patient-specific nutrition management also supports the use of specialized parenteral nutrition therapies across acute and long-term care settings.

Asia Pacific is expected to experience the fastest growth in the parenteral nutrition market as healthcare infrastructure expands and access to advanced hospital-based nutritional therapies improves. Rising healthcare expenditure, increasing awareness of clinical nutrition, and the expansion of intensive care and specialized medical services are broadening the addressable patient base. Growing demand from neonatal, surgical, oncology, and critically ill patient populations is encouraging healthcare providers to strengthen nutritional support capabilities. Improvements in hospital standards, pharmaceutical supply networks, and professional expertise are likely to accelerate adoption across both established and emerging healthcare systems in the region.

Key Country Insights

United States

Hospital Nutrition Innovation

The U.S. parenteral nutrition market emphasizes advanced clinical nutrition formulations, home infusion expansion, and resilient sterile manufacturing capacity. Healthcare providers in the U.S. continue to prioritize product reliability, safety standards, and specialized nutrition solutions for complex patient populations.

Japan

Aging Care Nutrition

Japan's parenteral nutrition market is shaped by the clinical needs of an aging population requiring long-term nutritional support. Healthcare providers in Japan emphasize safe formulations, infection control, and efficient hospital-based nutrition management for vulnerable patients.

South Korea

Advanced Hospital Integration

South Korea integrates parenteral nutrition products within technologically advanced hospital systems focused on specialized patient care. The market in South Korea supports demand for high-quality sterile preparations, improved clinical efficiency, and expanding use in intensive care settings.

Germany

Clinical Quality Focus

Germany prioritizes high-quality parenteral nutrition products supported by established hospital pharmacy practices and strict quality requirements. Demand in Germany increasingly centers on customized formulations, dependable supply chains, and efficient hospital procurement strategies.

France

Specialized Clinical Supply

France focuses on clinically standardized parenteral nutrition supported by centralized healthcare procurement and specialized hospital care. Healthcare institutions across France value consistent product availability, regulatory compliance, and tailored nutrition support for complex treatment pathways.

Italy

Compounding Care Excellence

Italy maintains strong demand for parenteral nutrition through hospital pharmacies and clinical nutrition services serving acute and chronic care patients. The Italian market emphasizes customized compounding capabilities, product quality, and dependable supply for healthcare facilities.

Segment Leadership and Growth Trends

 

Stage Type Segment Analysis: Adult (Largest Segment) vs Pediatrics (Fastest-Growing Segment)

The adult segment dominated the parenteral nutrition market, accounting for the largest share of 82.75% in 2026. Its leading position is supported by the substantial need for nutritional support among adult patients who are unable to obtain adequate nutrition through oral or enteral routes because of critical illness, gastrointestinal disorders, surgical interventions, or prolonged hospitalization. Adult parenteral nutrition protocols are widely established across hospital settings, where individualized formulations can address varying requirements for calories, proteins, electrolytes, vitamins, and other essential nutrients. Growing emphasis on clinical nutrition management and improved monitoring of patients requiring intravenous nutritional support further reinforces demand for adult-focused parenteral nutrition solutions.

The pediatrics segment is the fastest-growing segment, supported by increasing recognition of specialized nutritional requirements among infants and children with complex medical conditions. Pediatric patients may require parenteral nutrition when premature birth, congenital disorders, gastrointestinal dysfunction, or severe illness limits their ability to receive sufficient enteral nutrition. Greater attention to precise nutrient formulation, weight- and condition-specific nutritional management, and safer administration practices is encouraging broader adoption of pediatric parenteral nutrition. Advances in neonatal and pediatric critical care are also creating a stronger clinical environment for nutritional interventions tailored to younger patients.

Sales Channel Segment Analysis: Institutional (Largest Segment) vs Online (Fastest-Growing Segment)

In the parenteral nutrition market, the institutional segment held the largest share of 50.99% in 2026. Hospitals, clinics, and other healthcare institutions remain central to the delivery of parenteral nutrition because these products require clinical assessment, prescription, preparation, administration, and patient monitoring. Institutional purchasing also supports consistent access to specialized nutritional formulations for patients receiving intensive or long-term care. The need for controlled handling and professional oversight, together with the concentration of patients requiring intravenous nutrition within healthcare facilities, continues to sustain the segment's leading position.

The online segment is experiencing the fastest growth as healthcare procurement becomes increasingly digitized and buyers seek convenient access to specialized nutritional products and related supplies. Online channels can streamline product discovery, ordering, inventory management, and replenishment, particularly for healthcare providers and patients managing ongoing nutritional requirements outside traditional purchasing environments. Improvements in digital commerce infrastructure, broader acceptance of remote purchasing, and greater demand for convenient supply access are supporting the expansion of online distribution within the parenteral nutrition ecosystem.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Stage Type	Adult, Pediatrics	Adult	Pediatrics
Sales Channel	Online, Retail, Institutional	Institutional	Online
Nutrient Type	Carbohydrates, Parenteral Lipid Emulsion, Single Dose Amino Acid Solution, Trace Elements, Vitamins & Minerals	Single Dose Amino Acid Solution	Parenteral Lipid Emulsion
Indication	Alzheimer's, Nutrition Deficiency, Cancer, Diabetes, Chronic Kidney Diseases, Orphan Diseases, Dysphagia, Pain Management, Malabsorption/GI Disorder/Diarrhea, Others	Cancer	Dysphagia

Competitive Landscape and Market Positioning

Leading companies in the parenteral nutrition market:

1. Baxter International Inc. (United States)

2. Fresenius Kabi AG (Germany)

3. B. Braun SE (B. Braun Melsungen AG) (Germany)

4. Otsuka Pharmaceutical Factory Inc. (Japan)

5. Grifols S.A. (Spain)

6. Pfizer Inc. (United States)

7. ICU Medical Inc. (United States)

8. Sichuan Kelun Pharmaceutical Co. Ltd. (China)

9. JW Pharmaceutical Corporation (South Korea)

10. CSL Limited (Australia)

The parenteral nutrition market is witnessing continuous evolution driven by innovation in specialized nutritional formulations. Development efforts are increasingly focused on addressing complex patient-specific needs through improved composition science. Strategic consolidation activities are reshaping operational capabilities and enabling broader reach across care settings. Expansion into new therapeutic nutrition segments is further strengthening market adaptability and responsiveness.

Industry Development/News

Company Name	Date	Key Development
H.I.G. Capital	Jun-25	H.I.G. Capital finalized the acquisition of ITH Group, a prominent provider of aseptic pharmaceutical compounding services. The transaction directly strengthens operational compounding capabilities required for customized, sterile parenteral nutrition formulations across the healthcare sector.
Orbicular, Gland Pharma, Apotex	Apr-26	Orbicular, Gland Pharma, and Apotex secured U.S. FDA regulatory approval for a generic version of INFUVITE ADULT injectable, a critical clinical parenteral nutrition therapy. The Competitive Generic Therapy designation awards six months of domestic market exclusivity, shifting competitive dynamics.
Pharmbio Korea	Dec-25	Pharmbio Korea achieved domestic regulatory clearance for Neonatrium Injection, establishing South Korea’s first locally developed sodium acetate injectable product. The formulation serves as an essential electrolyte constituent used within custom parenteral nutrition preparations.
Fresenius Kabi Korea	Apr-24	Fresenius Kabi Korea introduced Ntense Injection and Ntense EF Injection, two specialized high-amino-acid intravenous clinical formulations. The multi-chamber products are commercialized to deliver targeted calories, amino acids, essential fatty acids, and omega-3s for pediatric and adult patient populations requiring parenteral support.
Rela Hospital	Mar-25	Rela Hospital launched the first dedicated Centre for Intestinal Rehabilitation and Nutrition Support in Mumbai, India. The new facility expands regional healthcare infrastructure specifically optimized for the management and distribution of long-term parenteral nutrition therapies.
American Regent	Mar-22	American Regent introduced its Selenious Acid Injection, USP, in a single-dose vial format. The trace element formula is commercialized for adult, pediatric, and neonatal patients under 7 kilograms, directly addressing nutritional deficits in clinical cohorts restricted from receiving oral or enteral nutrition.
VAV Lipids	Apr-24	VAV Lipids expanded manufacturing and operational capacity to meet global demand for specialized pharmaceutical-grade egg yolk lecithin. The lipid component functions as a critical raw ingredient required to manufacture commercial lipid emulsions within advanced parenteral nutrition formulations.